{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Galactionova K"],"pubmed_abstract":["Background
Patients with hormone receptor-positive, HER2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of relapse. PENELOPE-B was a double-blind, placebo-controlled, phase III trial that investigated adding palbociclib (PAL) for thirteen 28-day cycles to adjuvant endocrine therapy (ET) in these patients. Clinical results showed no significant improvement in invasive disease-free survival with PAL.Methods
We performed a pre-planned cost-effectiveness analysis of PAL within PENELOPE-B from the perspective of the German statutory health insurance. Health-related quality of life scores, collected in the trial using the EQ-5D-3L instrument, were converted to utilities based on the German valuation algorithm. Re"],"journal":["Frontiers in oncology"],"pagination":["886831"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9484462"],"repository":["biostudies-literature"],"pubmed_title":["Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial."],"pmcid":["PMC9484462"],"pubmed_authors":["McCarthy N","Marme F","Makris A","Rugo HS","Bonnefoi HR","Toi M","Schwenkglenks M","Kelly CM","Reimer T","Garcia-Saenz JA","Burchardi N","Kim SB","Bear HD","Gnant M","Gelmon KA","Loibl S","Untch M","Martin M","Galactionova K","Salari P"],"additional_accession":[]},"is_claimable":false,"name":"Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.","description":"Background
Patients with hormone receptor-positive, HER2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of relapse. PENELOPE-B was a double-blind, placebo-controlled, phase III trial that investigated adding palbociclib (PAL) for thirteen 28-day cycles to adjuvant endocrine therapy (ET) in these patients. Clinical results showed no significant improvement in invasive disease-free survival with PAL.Methods
We performed a pre-planned cost-effectiveness analysis of PAL within PENELOPE-B from the perspective of the German statutory health insurance. Health-related quality of life scores, collected in the trial using the EQ-5D-3L instrument, were converted to utilities based on the German valuation algorithm. Re","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-18T22:23:59.742Z","creation":"2024-11-09T20:50:54.882Z"},"accession":"S-EPMC9484462","cross_references":{"pubmed":["36132153"],"doi":["10.3389/fonc.2022.886831"]}}